Login to Your Account

As Antegren Makes Fast Tracks, Elan Bolsters Pain Drug NDA

By Randall Osborne

Wednesday, June 30, 2004
In a move that could markedly quicken the approval pace for its snail-based synthetic pain drug, Prialt, Elan Corp. plc added encouraging Phase III data to the new drug application and expects a review time of about six months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription